Loading...
•
Mar 31, 2022
Mirum Pharmaceuticals Q1 2022 Earnings Report
Mirum Pharmaceuticals reported financial results for the first quarter ended March 31, 2022 and provided a business update.
Key Takeaways
Mirum Pharmaceuticals reported a successful first quarter with total revenue of $12.9 million, including $10.9 million from LIVMARLI® product revenue. The company's net loss was $36.6 million, or $1.17 per share, and it had $239.9 million in cash, cash equivalents, and investments as of March 31, 2022.
Total revenue for Q1 2022 was $12.9 million.
Net product revenue for LIVMARLI® was $10.9 million.
The company reported a net loss of $36.6 million, or $1.17 net loss per share.
Mirum had cash, cash equivalents, restricted cash equivalents, and investments of $239.9 million as of March 31, 2022.
Forward Guidance
Mirum Pharmaceuticals anticipates several milestones in the near future, including topline data from the MARCH-PFIC Phase 3 trial, potential LIVMARLI approval by the European Medicines Agency, interim analysis for VISTAS and OHANA Phase 2b clinical trials, and interim analysis for VANTAGE Phase 2b clinical trial in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...